Department of Pathology, School of Medicine, CEGIN-BIOREN, Universidad de La Frontera, Temuco, Chile.
Arch Pathol Lab Med. 2013 Feb;137(2):245-50. doi: 10.5858/arpa.2011-0628-OA.
Gallbladder cancer (GBC) is an aggressive neoplasia associated with late diagnosis, unsatisfactory treatment, and poor prognosis. Molecular mechanisms involved in GBC pathogenesis remain poorly understood. Connective tissue growth factor (CTGF) is thought to play a role in the pathologic processes and is overexpressed in several human cancers, including GBC. No information is available about CTGF expression in early stages of gallbladder carcinogenesis. Objective.- To evaluate the expression level of CTGF in benign and malignant lesions of gallbladder and its correlation with clinicopathologic features and GBC prognosis.
Connective tissue growth factor protein was examined by immunohistochemistry on tissue microarrays containing tissue samples of chronic cholecystitis (n = 51), dysplasia (n = 15), and GBC (n = 169). The samples were scored according to intensity of staining as low/absent and high CTGF expressers. Statistical analysis was performed using the χ(2) test or Fisher exact probability test with a significance level of P < .05. Survival analysis was assessed by the Kaplan-Meier method and the log-rank test.
Connective tissue growth factor expression showed a progressive increase from chronic cholecystitis to dysplasia and then to early and advanced carcinoma. Immunohistochemical expression (score ≥2) was significantly higher in advanced tumors, in comparison with chronic cholecystitis (P < .001) and dysplasia (P = .03). High levels of CTGF expression correlated with better survival (P = .04).
Our results suggest a role for CTGF in GBC progression and a positive association with better prognosis. In addition, they underscore the importance of considering the involvement of inflammation on GBC development.
胆囊癌(GBC)是一种侵袭性肿瘤,其诊断较晚,治疗效果不佳,预后较差。GBC 发病机制中的分子机制仍知之甚少。结缔组织生长因子(CTGF)被认为在病理过程中起作用,并在包括 GBC 在内的几种人类癌症中过度表达。关于 CTGF 在胆囊癌发生的早期阶段的表达尚无信息。目的:评估 CTGF 在胆囊良性和恶性病变中的表达水平及其与临床病理特征和 GBC 预后的关系。
采用组织微阵列免疫组织化学法检测慢性胆囊炎(n = 51)、异型增生(n = 15)和 GBC(n = 169)组织样本中的 CTGF 蛋白。根据染色强度将标本评分,分为低/无 CTGF 表达者和高 CTGF 表达者。采用卡方检验或 Fisher 确切概率检验进行统计学分析,P <.05 为差异有统计学意义。采用 Kaplan-Meier 法和对数秩检验进行生存分析。
CTGF 表达从慢性胆囊炎到异型增生再到早期和晚期癌逐渐增加。与慢性胆囊炎(P <.001)和异型增生(P =.03)相比,晚期肿瘤的免疫组织化学表达(评分≥2)显著更高。高水平的 CTGF 表达与更好的生存相关(P =.04)。
我们的结果表明 CTGF 在 GBC 进展中起作用,并与更好的预后呈正相关。此外,它们强调了考虑炎症对 GBC 发展的重要性。